In yesterday’s Wall Street session, Guardion Health Sciences Inc. (NASDAQ:GHSI) shares traded at $0.14, down -0.69% from the previous session.
1 analysts cover Guardion Health Sciences Inc. (NASDAQ:GHSI), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $0.60 and a low of $0.60, we find $0.60. Given the previous closing price of $0.14, this indicates a potential upside of 328.57 percent. GHSI stock price is now -11.25% away from the 50-day moving average and -14.40% away from the 200-day moving average. The market capitalization of the company currently stands at $9.14M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $0.60 as their price target over the next twelve months.
.
Insiders disposed of 37,175 shares of company stock worth roughly $5204.500000000001 over the past 1 year. A total of 1.34% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GHSI stock. A new stake in Guardion Health Sciences Inc. shares was purchased by ERGOTELES LLC during the first quarter worth $20,000. BALYASNY ASSET MANAGEMENT LLC invested $6,000 in shares of GHSI during the first quarter. In the first quarter, RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. acquired a new stake in Guardion Health Sciences Inc. valued at approximately $2,000. CORECAP ADVISORS, LLC acquired a new stake in GHSI for approximately ,000. In total, there are 22 active investors with 7.70% ownership of the company’s stock.
On Thursday morning Guardion Health Sciences Inc. (NASDAQ: GHSI) stock kicked off with the opening price of $0.1440. During the past 12 months, Guardion Health Sciences Inc. has had a low of $0.13 and a high of $0.76. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 10.30, and a quick ratio of 9.10. The fifty day moving average price for GHSI is $0.1623 and a two-hundred day moving average price translates $0.1683 for the stock.
The latest earnings results from Guardion Health Sciences Inc. (NASDAQ: GHSI) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.03, beating analysts’ expectations of -$0.04 by 0.01. This compares to -$0.12 EPS in the same period last year. The company reported revenue of $2.66 million for the quarter, compared to $3.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -15.4 percent. For the current quarter, analysts expect GHSI to generate $3.55M in revenue.
Guardion Health Sciences Inc.(GHSI) Company Profile
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
